Clin Exp Vaccine Res.  2013 Jan;2(1):26-33.

H9N2 avian influenza virus in Korea: evolution and vaccination

• Lee DH
• Song CS

Abstract

Low pathogenic avian influenza (LPAI) H9N2 viruses have been circulating in the Eurasian poultry industry resulting in great economic losses due to declined egg production and moderate to high mortality. In Korea, H9N2 LPAI was first documented in 1996 and it caused serious economic loss in the Korean poultry industry, including layer and broiler breeder farms. Since then, the H9N2 viruses that belong to the Korea group have been prevalent in chickens and have continuously evolved through reassortment in live bird markets. To control LPAI outbreaks, since 2007, the Korean veterinary authority has permitted the use of the inactivated oil adjuvant H9N2 LPAI vaccine. Although only oil-based inactivated vaccine using the egg-passaged vaccine virus strain (A/chicken/Korea/01310/2001) is permitted and used, several new technology vaccines have been recently suggested for the development of cost-effective and highly immunogenic vaccines. In addition, several different differentiation of infected from vaccinated animals (DIVA) strategies have been suggested using appropriate vaccines and companion serologic tests for discriminating between naturally infected and vaccinated animals. Recent reports demonstrated that the Korean LPAI H9N2 virus underwent antigenic drift and evolved into distinct antigenic groups and thus could escape from vaccine protection. Therefore, improved vaccination strategies including periodic updates of vaccine seed strains are required to achieve efficient control and eradication of LPAI H9N2 in Korea. Further, vaccination should be part of an overall integrated strategy to control the disease, including continued nation-wide surveillance, farm biosecurity, and DIVA strategy.

Keyword

Avian influenza virus; H9N2; Vaccine; Evolution

MeSH Terms

Animals
Birds
Chickens
Disease Outbreaks
Friends
Humans
Influenza A Virus, H9N2 Subtype
Influenza in Birds
Korea
Ovum
Poultry
Seeds
Serologic Tests
Sprains and Strains
United Nations
Vaccination
Vaccines
Viruses
Vaccines

Figure

• 

  Fig. 1 Role of live bird markets in facilitating the evolution of low pathogenic avian influenza H9N2 virus in Korea. The H9N2 viruses that belong to the Korea group have continuously evolved by antigenic drift and have undergone reassortment with avian influenza virus genes from wild bird isolates, poultry farm isolates, and minor poultry isolates in the Korean live bird markets.

Reference

1. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992. 56:152–179.

2. Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine. 2007. 25:5637–5644.

3. Rott R. The pathogenic determinant of influenza virus. Vet Microbiol. 1992. 33:303–310.

4. Munster VJ, Fouchier RA. Avian influenza virus: of virus and bird ecology. Vaccine. 2009. 27:6340–6344.

5. Matrosovich MN, Krauss S, Webster RG. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology. 2001. 281:156–162.

6. Butt AM, Siddique S, Idrees M, Tong Y. Avian influenza A (H9N2): computational molecular analysis and phylogenetic characterization of viral surface proteins isolated between 1997 and 2009 from the human population. Virol J. 2010. 7:319.

7. Guan Y, Shortridge KF, Krauss S, Webster RG. Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Proc Natl Acad Sci U S A. 1999. 96:9363–9367.

8. Guo YJ, Krauss S, Senne DA, et al. Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. Virology. 2000. 267:279–288.

9. Lee YJ, Shin JY, Song MS, et al. Continuing evolution of H9 influenza viruses in Korean poultry. Virology. 2007. 359:313–323.

10. Monne I, Cattoli G, Mazzacan E, et al. Genetic comparison of H9N2 AI viruses isolated in Jordan in 2003. Avian Dis. 2007. 51:1 Suppl. 451–454.

11. Toroghi R, Momayez R. Biological and molecular characterization of Avian influenza virus (H9N2) isolates from Iran. Acta Virol. 2006. 50:163–168.

12. Wu R, Sui ZW, Zhang HB, et al. Characterization of a pathogenic H9N2 influenza A virus isolated from central China in 2007. Arch Virol. 2008. 153:1549–1555.

13. Butt KM, Smith GJ, Chen H, et al. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol. 2005. 43:5760–5767.

14. Lin YP, Shaw M, Gregory V, et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A. 2000. 97:9654–9658.

15. Butler D. Vaccination will work better than culling, say bird flu experts. Nature. 2005. 434:810.

16. Capua I, Marangon S. The use of vaccination as an option for the control of avian influenza. Avian Pathol. 2003. 32:335–343.

17. Naeem K, Siddique N, Ayaz M, Jalalee MA. Avian influenza in Pakistan: outbreaks of low- and high-pathogenicity avian influenza in Pakistan during 2003-2006. Avian Dis. 2007. 51:1 Suppl. 189–193.

18. Perk S, Panshin A, Shihmanter E, et al. Ecology and molecular epidemiology of H9N2 avian influenza viruses isolated in Israel during 2000-2004 epizootic. Dev Biol (Basel). 2006. 124:201–209.

19. Lee CW, Song CS, Lee YJ, et al. Sequence analysis of the hemagglutinin gene of H9N2 Korean avian influenza viruses and assessment of the pathogenic potential of isolate MS96. Avian Dis. 2000. 44:527–535.

20. Kwon HJ, Cho SH, Kim MC, Ahn YJ, Kim SJ. Molecular epizootiology of recurrent low pathogenic avian influenza by H9N2 subtype virus in Korea. Avian Pathol. 2006. 35:309–315.

21. Choi YK, Seo SH, Kim JA, Webby RJ, Webster RG. Avian influenza viruses in Korean live poultry markets and their pathogenic potential. Virology. 2005. 332:529–537.

22. Kim HR, Park CK, Oem JK, et al. Characterization of H5N2 influenza viruses isolated in South Korea and their influence on the emergence of a novel H9N2 influenza virus. J Gen Virol. 2010. 91(Pt 8):1978–1983.

23. Kim JA, Cho SH, Kim HS, Seo SH. H9N2 influenza viruses isolated from poultry in Korean live bird markets continuously evolve and cause the severe clinical signs in layers. Vet Microbiol. 2006. 118:169–176.

24. Lee HJ, Kwon JS, Lee DH, et al. Continuing evolution and interspecies transmission of influenza viruses in live bird markets in Korea. Avian Dis. 2010. 54:1 Suppl. 738–748.

25. Lee HJ, Lee DH, Lee YN, et al. Generation of reassortant influenza viruses within the non-industrial poultry system. Infect Genet Evol. 2012. 12:933–946.

26. Moon HJ, Song MS, Cruz DJ, et al. Active reassortment of H9 influenza viruses between wild birds and live-poultry markets in Korea. Arch Virol. 2010. 155:229–241.

27. Liu M, He S, Walker D, et al. The influenza virus gene pool in a poultry market in South central china. Virology. 2003. 305:267–275.

28. Kwon YK, Lee YJ, Choi JG, et al. An outbreak of avian influenza subtype H9N8 among chickens in South Korea. Avian Pathol. 2006. 35:443–447.

29. Lee DH, Lee HJ, Lee YN, et al. Evidence of intercontinental transfer of North American lineage avian influenza virus into Korea. Infect Genet Evol. 2011. 11:232–236.

30. Choi JG, Lee YJ, Kim YJ, et al. An inactivated vaccine to control the current H9N2 low pathogenic avian influenza in Korea. J Vet Sci. 2008. 9:67–74.

31. Suarez DL. Overview of avian influenza DIVA test strategies. Biologicals. 2005. 33:221–226.

32. Lee YJ, Sung HW, Choi JG, et al. Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza. Avian Dis. 2007. 51:1 Suppl. 476–478.

33. Lee DH, Park JK, Lee YN, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine. 2011. 29:4003–4007.

34. Kwon JS, Kim MC, Jeong OM, et al. Novel use of a N2-specific enzyme-linked immunosorbent assay for differentiation of infected from vaccinated animals (DIVA)-based identification of avian influenza. Vaccine. 2009. 27:3189–3194.

35. Kim MC, Choi JG, Kwon JS, et al. Field application of the H9M2e enzyme-linked immunosorbent assay for differentiation of H9N2 avian influenza virus-infected chickens from vaccinated chickens. Clin Vaccine Immunol. 2010. 17:1977–1984.

36. Engelhardt OG. Many ways to make an influenza virus: review of influenza virus reverse genetics methods. Influenza Other Respi Viruses. 2012. [Epub]. http://dx.doi.org/10.1111/j.1750-2659.2012.00392.x.

37. Neumann G, Ozawa M, Kawaoka Y. Reverse genetics of influenza viruses. Methods Mol Biol. 2012. 865:193–206.

38. Song JM, Lee YJ, Jeong OM, et al. Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea. Vet Microbiol. 2008. 130:268–276.

39. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010. 9:1149–1176.

40. Kang SM, Compans RW. Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Mol Cells. 2009. 27:5–14.

41. Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res. 2009. 143:140–146.

42. Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010. 28:4771–4776.

43. Park JK, Lee DH, Youn HN, et al. Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respi Viruses. 2012. [Epub]. http://dx.doi.org/10.1111/j.1750-2659.2012.00396.x.

44. Prel A, Le Gall-Recule G, Jestin V. Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks. Avian Pathol. 2008. 37:513–520.

45. Prel A, Le Gall-Recule G, Cherbonnel M, Grasland B, Amelot M, Jestin V. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Dis. 2007. 51:1 Suppl. 484–489.

46. Lee DH, Kwon JS, Lee HJ, et al. Inactivated H9N2 avian influenza virus vaccine with gel-primed and mineral oil-boosted regimen could produce improved immune response in broiler breeders. Poult Sci. 2011. 90:1020–1022.

47. Swayne DE, Suarez DL. Highly pathogenic avian influenza. Rev Sci Tech. 2000. 19:463–482.

48. Sun Y, Pu J, Fan L, et al. Evaluation of the protective efficacy of a commercial vaccine against different antigenic groups of H9N2 influenza viruses in chickens. Vet Microbiol. 2012. 156:193–199.

49. Park KJ, Kwon HI, Song MS, et al. Rapid evolution of low-pathogenic H9N2 avian influenza viruses following poultry vaccination programmes. J Gen Virol. 2011. 92(Pt 1):36–50.

50. Lee CH, Byun SH, Lee YJ, Mo IP. Genetic evolution of the H9N2 avian influenza virus in Korean poultry farms. Virus Genes. 2012. 45:38–47.

51. Lee YN, Lee DH, Park JK, et al. Isolation and characterization of a novel H9N2 influenza virus in Korean native chicken farm. Avian Dis. 2011. 55:724–727.

52. Grenfell BT, Pybus OG, Gog JR, et al. Unifying the epidemiological and evolutionary dynamics of pathogens. Science. 2004. 303:327–332.